Unlock instant, AI-driven research and patent intelligence for your innovation.

Using trbv family members to predict the efficacy of trastuzumab neoadjuvant therapy in breast cancer patients kit and its application

A technology of breast cancer and reagents, applied in the field of biomedicine, to achieve the effect of prolonging disease-free survival and overall survival

Active Publication Date: 2020-05-05
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Most previous studies simply quantified the number of T lymphocytes in tumor tissue, but T lymphocytes are a very heterogeneous population of immune cells, and there is also molecular diversity in the T cell receptor (TCR)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Using trbv family members to predict the efficacy of trastuzumab neoadjuvant therapy in breast cancer patients kit and its application
  • Using trbv family members to predict the efficacy of trastuzumab neoadjuvant therapy in breast cancer patients kit and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1 Screening of gene markers related to the efficacy of trastuzumab combined with chemotherapy drugs in the treatment of breast cancer patients

[0053] 1. Sample collection

[0054] 1.1 Inclusion criteria

[0055] The study included 26 patients with pathologically confirmed ER / PR-negative HER2-positive invasive breast cancer, with an average age of 48 years and clinical stages of II-III patients. 21 patients received 4-6 cycles of trastuzumab combined with Paclitaxel + carboplatin therapy (TCH) neoadjuvant therapy, 5 patients received trastuzumab combined with epirubicin + paclitaxel (ATH) neoadjuvant therapy. The patient had not previously received any other anti-tumor therapy (including radiotherapy, chemotherapy, targeted therapy, and endocrine therapy) for breast cancer. Among them, 11 patients achieved pathological complete remission (pCR) and 15 patients had non-complete remission (non-pCR).

[0056] 1.2 Collection of samples and clinical data

[0057]...

Embodiment 2

[0086] Verification of Example 2 Differential Genes in Large Samples

[0087] 1. Sample collection

[0088] 1.1 Inclusion criteria

[0089] The study included 80 patients with pathologically confirmed ER / PR-negative HER2-positive invasive breast cancer, with an average age of 47 years, and the patients were in clinical stage II-III. Thirty-two patients received neoadjuvant therapy of trastuzumab combined with epirubicin and paclitaxel (ATH), and 48 patients received neoadjuvant therapy of trastuzumab combined with paclitaxel and carboplatin (TCH). According to statistics, there were 49 patients with non-pCR and 31 patients with pCR.

[0090] 1.2 Total RNA extraction from blood

[0091] After obtaining informed consent from the patients, peripheral blood samples were collected from the patients before treatment.

[0092] (1) Fresh whole blood, erythrocyte lysate (1:1), mix by inverting several times, let stand for 5 minutes. 10000g, 4°C, 10min. At this time, the white blo...

Embodiment 3

[0113] Example 3 Kit for Predicting the Curative Effect of Trastuzumab Combined with Chemotherapeutic Drugs in Patients with HER2-Positive Breast Cancer

[0114]According to the correlation between TRBV12-3 gene and TRBV12-5 gene and the responsiveness of breast cancer patients to trastuzumab combined with chemotherapy drugs, it can be predicted by detecting the expression of TRBV12-3 gene and / or TRBV12-5 gene The curative effect of trastuzumab combined with chemotherapeutic drugs in the treatment of HER2 positive breast cancer patients. Accordingly, the present invention provides a kit for predicting the curative effect of trastuzumab combined with chemotherapeutic drugs in the treatment of HER2 positive breast cancer patients. The components are as follows: SYBR Green polymerase chain reaction system, primer pair for amplifying TRBV12-3 gene and / or TRBV12-5 gene, and GAPDH gene, M-MLV reverse transcription system, and RNA extraction reagent. Amplify the forward sequence 5'-A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicines, and discloses an application of TRBV12-3 and / or TRBV12-5 genes to forecasting of combined therapy effects of breast cancer patients by trastuzumab and chemotherapeutic agents. Experiments prove that the gene frequency and the gene expression amount of the TRBV12-3 gene and the TRBV12-5 gene of therapy effect pCR patients in peripheral T-cells are remarkably lower than those of therapy effect non-pCR patients, and the TRBV12-3 and the TRBV12-5 can be used for developing products for forecasting the combined therapy effects of the breast cancer patients by the trastuzumab and the chemotherapeutic agents. The invention further discloses the TRBV12-3 and TRBV12-5 genes capable of serving as therapeutic targets of breast cancers. Research results provide fundamental basis for making personalized therapeutic schedules by clinicians and can provide new drug targets for development of the breast cancer drugs.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of TRBV family members in predicting the curative effect of medicines. Background technique [0002] Breast cancer is currently the most common malignant tumor in women. GLOBOCAN 2012 data shows that in 2012, there were 1.7 million new cases of breast cancer in the world, with a total death of 522,000 cases, ranking second in the cause of cancer death in women. Therefore, its efficacy prediction and improved prognosis have always been important Research priorities for clinical researchers. In patients with locally advanced or high biological risk breast cancer, neoadjuvant therapy is used to shrink tumor burden to increase curative resection and breast-conserving rates and reduce the risk of disease recurrence and death. Hormone receptor (HR) negative expression and HER2 overexpression are molecular biological factors associated with breast cancer disease progression and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886C12Q2600/106C12Q2600/158G01N33/57415
Inventor 马飞徐兵河王文娜管彦芳陈文挺王玉奇
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI